Impact of 131I treatment on health-related quality of life in female patients with early stage papillary thyroid cancer

马庆杰,柏林,温强,张露月,高识,赵劼,赵敏

DOI: https://doi.org/10.3760/cma.j.cn121381-202004010-00006

2021-01-01

Abstract:Objective:To analyze the effect of 131I treatment on health-related quality of life (HRQOL) in female patients with early stage thyroid papillary carcinoma (PTC). Methods:The data of 356 female PTC patients (aged 21-65 (41.00±9.64) years) with pT1N1aM0 in China-Japan Union Hospital of Jilin University collected from June 2015 to June 2016 were retrospectively analyzed. A total of 400 healthy women (aged 21-65 (41.70±9.38) years) were selected as healthy controls. The HRQOL scores by the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire-core 30(QLQ-C30) between the controls and PTC patients at preoperative period and at 6 months after the operation were compared. Patients were divided into two groups according to whether or not they received 131I treatment ( 131I treatment group: n=205, non- 131I treatment group: n=151). The levels of thyroid-stimulating hormone (TSH), thyroglobulin (Tg), and HRQOL scores at preoperative period and at 1, 3, and 6 months after the operation were compared between the two groups. Informed consent was obtained from all subjects. Non-parametric test of Mann-Whitney U was used to compare the groups with SPSS 19.0 software. Results:Before the operation, the global quality of life (GQOL) score of all patients was significantly lower than that of the controls (59.11±21.12 vs. 83.08±14.62), functional domain scores in patients were lower than those in the controls except physical function, symptom domain scores were significantly higher except pain ( Z=-6.958 to -4.673, all P<0.05). At 6 months after operation, the GQOL score in patients was still lower than that in the controls (73.88±18.04 vs. 83.08±14.62), but it was significantly higher than the preoperative score. Similar improvements were found in eight other domains other than physical function, cognitive function, social function, fatigue, pain and dyspnoea ( Z=-5.790 to -2.876, all P<0.05). No significant difference was found in the preoperative all-domain scores between the 131I and non- 131I treatment groups ( Z=-0.876 to -0.001, all P>0.05). TSH and Tg in 131I treatment group were significantly higher than non- 131I treatment group at 1 month after operation ( Z=-6.159, -10.061, both P<0.01). At 1 month after operation, the GQOL score in the 131I treatment group was significantly lower than that in the non- 131I treatment group (50.57±17.72 vs. 55.74±18.82). Functional domain scores of the 131I treatment group were significantly lower than those in the non- 131I treatment group, symptom domain scores were significantly higher except pain, diarrhea, and financial impact ( Z=-5.512 to -2.550, all P<0.05). At 3 months after operation, the GQOL score of the 131I treatment group was still lower than that in the non- 131I treatment group (64.43±32.12 vs. 72.68±17.29), but the functional domain scores of the 131I treatment group were lower than that in the non- 131I treatment group only in the role function, emotional function, social function, and symptom domain scores were higher only in the insomnia, appetite loss ( Z=-2.939 to -0.984, all P<0.05). At 6 months after operation, no difference was found in the GQOL score and any other scores between the 131I treatment group and non- 131I treatment group ( Z=-2.550 to -0.008, all P>0.05). Conclusion:131I treatment had no impact on HRQOL in female patients with early stage PTC at 6 months after the operation or longer.